CLOV · ISSUER CIK 1801170
CLOVER HEALTH INVESTMENTS, CORP. /DE
Between Aug 1, 2026 and Oct 29, 2026, 8 CLOVER HEALTH INVESTMENTS, CORP. /DE insiders reported $0.00 of open-market purchases and $4.2M of sales on SEC Form 4.
↗8 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 17 of 18 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$4.2MInsider selling
−$4.2MNet open-market
Oct 20, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 20, 202617:56 | Oct 20, 2026 | CLOV | Chief Legal Officer | S · Sell10b5-1 | $4.66 | −19,275 | 1,573,423 | -1% | −$90K | ||
| Oct 20, 202616:43 | Oct 19, 2026 | CLOV | CEO, Medicare Advantage | S · Sell10b5-1 | $4.41 | −4,066 | 2,770,351 | -0% | −$18K | ||
| Oct 19, 202616:31 | Oct 15, 2026 | CLOV | Chief Executive Officer, Director | S · Sell10b5-1 | $4.68 | −62,176 | 9,078,334 | -1% | −$291K | ||
| Oct 19, 202616:26 | Oct 15, 2026 | CLOV | Chief Legal Officer | S · Sell10b5-1 | $4.68 | −14,673 | 1,592,698 | -1% | −$69K | ||
| Oct 19, 202616:23 | Oct 15, 2026 | CLOV | Interim CFO | S · Sell10b5-1 | $4.68 | −4,591 | 1,244,935 | -0% | −$21K | ||
| Oct 19, 202616:22 | Oct 15, 2026 | CLOV | CEO, Counterpart Health | S · Sell10b5-1 | $4.68 | −23,627 | 1,042,072 | -2% | −$111K | ||
| Oct 19, 202616:19 | Oct 15, 2026 | CLOV | CEO, Medicare Advantage | S · Sell10b5-1 | $4.68 | −18,273 | 2,774,417 | -1% | −$86K | ||
| Oct 7, 202618:20 | Oct 7, 2026 | CLOV | CEO, Medicare Advantage | S · Sell10b5-1 | $4.63 | −2,006 | 2,792,690 | -0% | −$9K | ||
| Oct 5, 202619:00 | Oct 5, 2026 | CLOV | CEO, Medicare Advantage | S · Sell10b5-1 | $4.42 | −8,750 | 2,794,696 | -0% | −$39K | ||
| Oct 2, 202616:15 | Sep 30, 2026 | CLOV | Director | A · Grant | — | +12,481 | 12,481 | New | — | ||
| Oct 2, 202616:14 | Sep 30, 2026 | CLOV | Director | A · Grant | — | +12,481 | 186,897 | +7% | — | ||
| Oct 2, 202616:12 | Oct 1, 2026 | CLOV | Chief Executive Officer, Director | S · Sell10b5-1 | $4.19 | −318,806 | 9,140,510 | -3% | −$1.3M | ||
| Sep 18, 202616:22 | Sep 17, 2026 | CLOV | CEO, Medicare Advantage | S · Sell10b5-1 | $4.56 | −1,921 | 2,803,446 | -0% | −$9K | ||
| Sep 17, 202617:29 | Sep 16, 2026 | CLOV | VP OF FINANCE AND CONTROLLER | S · Sell10b5-1 | $4.64 | −3,170 | 275,897 | -1% | −$15K | ||
| Sep 16, 202616:27 | Sep 15, 2026 | CLOV | CEO, Counterpart Health | S · Sell10b5-1 | $4.72 | −300,000 | 1,170,056 | -20% | −$1.4M | ||
| Sep 15, 202620:11 | Sep 15, 2026 | CLOV | Chief Legal Officer | S · Sell10b5-1 | $4.78 | −6,846 | 1,607,371 | -0% | −$33K | ||
| Sep 15, 202619:48 | Sep 15, 2026 | CLOV | CEO, Medicare Advantage | S · Sell10b5-1 | $4.78 | −9,273 | 2,805,367 | -0% | −$44K | ||
| Sep 14, 202620:52 | Sep 14, 2026 | CLOV | VP OF FINANCE AND CONTROLLER | S · Sell | $5.16 | −20,000 | 279,067 | -7% | −$103K | ||
| Aug 17, 202617:58 | Aug 17, 2026 | CLOV | Interim CFO | S · Sell10b5-1 | $4.39 | −17,775 | 1,249,526 | -1% | −$78K | ||
| Aug 13, 202616:23 | Aug 12, 2026 | CLOV | Chief Legal Officer | A · Grant | — | +108,695 | 1,614,217 | +7% | — | ||
| Aug 13, 202616:20 | Aug 12, 2026 | CLOV | Interim CFO | A · Grant | — | +54,347 | 1,267,301 | +4% | — | ||
| Aug 10, 202618:30 | Aug 10, 2026 | CLOV | Chief Executive Officer, Director | S · Sell10b5-1 | $4.65 | −87,798 | 9,459,316 | -1% | −$408K |